PRO1107 in Patients With Advanced Solid Tumors

Summary

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

Timeline

Start

2024-01-03

Primary completion

2025-08-18

Completion

2025-08-18

Outcome

Outcome not reported

Stopped: “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”

Drugs

Indications